5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor

CompletedOBSERVATIONAL
Enrollment

69

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Malignant Gliomas
Interventions
DRUG

Gliolan®

single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively

PROCEDURE

Fluorescence-Guided Surgery

performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.

Trial Locations (17)

10003

Mount Sinai Beth Israel, New York

10029

Icahn School of Medicine at Mount Sinai, New York

15212

Allegheny General Hospital, Pittsburgh

17033

Penn State- Milton S. Hershey Medical Center, Hershey

18015

St. Luke's University Health Network, Bethlehem

20037

George Washington University, Washington D.C.

30322

Winship Cancer Institute of Emory University, Atlanta

33484

Delray Medical Center, Delray Beach

48202

Henry Ford Hospital, Detroit

56303

CentraCare St. Cloud Hospital, Saint Cloud

63110

Washington University School of Medicine, St Louis

64111

St. Luke's Marion Bloch Neuroscience Institute, Kansas City

66160

University of Kansas Medical Center, Kansas City

83706

Saint Alphonsus Regional Medical Center, Boise

84112

Huntsman Cancer Institute, Salt Lake City

87131

University of New Mexico School of Medicine, Department of Neurosurgery, Albuquerque

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

lead

Constantinos Hadjipanayis

OTHER

NCT02632370 - 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor | Biotech Hunter | Biotech Hunter